Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Oxytetracycline→

Oxytetracycline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
79-57-2
Molecular formula
C22H24N2O9
Molecular weight
460.4 g/mol
Drug class
Tetracycline-class antibacterial30S ribosomal subunit inhibitor
Mechanism of action
Reversibly binds the 30S ribosomal subunit and prevents aminoacyl-tRNA attachment to the ribosomal acceptor site, inhibiting bacterial protein synthesis and producing mainly bacteriostatic activity.
Indications / reported uses
  • Treatment of infections caused by oxytetracycline-susceptible bacteria and selected atypical organisms where authorised; specific indications vary by oral, topical, ophthalmic and veterinary formulations and should follow local resistance guidance

Sources: NLM MeSH — Oxytetracycline · PubMed — Oxytetracycline pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Oxytetracycline Environmental Risk Assessment (ERA) (the Oxytetracycline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.